Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Randomized, Crossover Study to Assess the Safety and Pharmacokinetics Following Single Doses of Oral and Intravenous Xenleta (Lefamulin) in Adult Patients With Cystic Fibrosis

NCT05225805 is registered in ClinicalTrials.gov with Nabriva Therapeutics AG as lead sponsor.

NCT NCT05225805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05225805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Randomized, Crossover Study to Assess the Safety and Pharmacokinetics Following Single Doses of Oral and Intravenous Xenleta (Lefamulin) in Adult Patients With Cystic Fibrosis
Lead sponsor
Nabriva Therapeutics AG
Phase
Phase 1
Overall status
Completed
Start date
March 1, 2022
Completion date
January 13, 2023
Enrollment
13 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis